SORAFENIB(BAY43-9006) AND BLOOD PRESSURE

索拉非尼（BAY43-9006）和血压

• 批准号: 7378637
• 负责人: MARK J RATAIN
• 金额: $ 29.04万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-18 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378637
• 关键词: blood pressure; clinical trial phase III; hypertension; metabolism; neoplasm /cancer; plasma; renin; sodium

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Sorafenib is a new anti-cancer drug in Phase II and Phase III trials. During initial clinical studies, hypertension was noted among 10% of subjects. Further retrospective analysis of limited, non-standardized data suggest that blood pressure elevations may occur frequently in subjects receiving this drug and that these elevations may predict tumor responsiveness to the drug. The purpose of this study is to measure blood pressure more accurately and more frequently in subjects receiving sorafenib. Additional material will be collected to characterize the relationship among blood pressure elevations, plasma drug levels, and sodium and rennin metabolism.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。索拉非尼是一种正在进行第二阶段和第三阶段试验的抗癌新药。在最初的临床研究中，10%的受试者发现有高血压。对有限的、非标准化数据的进一步回顾分析表明，在接受该药物的受试者中，血压可能经常升高，这些升高可能预测肿瘤对该药物的反应。这项研究的目的是为了更准确、更频繁地测量服用索拉非尼的受试者的血压。将收集更多的材料来描述血压升高、血浆药物水平以及钠和肾素代谢之间的关系。